Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

ABSTRACT: Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives of abstracts from the European Hematology Association and the American Society of Hematology annual congresses from 2014 onward for randomized controlled trials comparing the treatment vs best available therapy (BAT). Our search retrieved 80 records; after screening of abstracts and full text, the total was reduced to 16. Evidence came from 4 randomized controlled trials, including 663 patients (1057 patients per year). We estimated a thrombosis risk ratio of 0.56 for ruxolitinib BAT, correspond

SUBMITTER: Masciulli A 

PROVIDER: S-EPMC6988397 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature